SCHEMBL1474617

SCHEMBL1474617

CCc1c(C(=O)O)oc2cccc(O)c12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
LMNA P02545 2/20 0.47
TSHR P16473 2/20 0.47
HSD17B10 Q99714 2/20 0.45
EDNRA P25101 2/20 0.44
MCL1 Q07820 3/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
CYP3A4 P08684 2/20 0.42
ALOX15 P16050 2/20 0.42
KDM4E B2RXH2 2/20 0.42
MAPK1 P28482 2/20 0.42
USP2 O75604 1/20 0.42
TP53 P04637 1/20 0.42
HPGD P15428 1/20 0.42
MAOA P21397 2/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP1A1 P04798 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9754478 0.80 EDNRA (0.42) MAPTNPC1RAB9ALMNATSHR
SCHEMBL3611742 0.78 MAPT (0.65) MAPTNPC1RAB9ALMNAHSD17B10
SCHEMBL1728009 0.77 HTR2B (0.45) MAPTNPC1RAB9ALMNATSHR
SCHEMBL10795690 0.77 NQO1 (0.48) MAPTNPC1RAB9ALMNATSHR
SCHEMBL2773751 0.77 MCL1 (0.58) MAPTNPC1RAB9ALMNATSHR
SCHEMBL30506421 0.76 MAPT (0.48) MAPTNPC1RAB9ALMNATSHR
SCHEMBL1474620 0.75 GABRA1 (0.47) MAPTNPC1RAB9ALMNAHSD17B10
SCHEMBL10791228 0.74 MAPT (0.49) MAPTNPC1RAB9ALMNATSHR
SCHEMBL17669713 0.74 L3MBTL1 (0.55) MAPTNPC1RAB9ATSHRHSD17B10
SCHEMBL5279040 0.74 EDNRA (0.62) MAPTNPC1RAB9ALMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915300-B2 Especially those of papain superfamily; prophylaxis or treatment of disorders stemming from misbalance of physiological proteases such as cathepsin K; (3aS,6S,6aS)-6-Fluoro-4-{(S)-4-methyl-2-[(R)-2,2,2-trifluoro-1-(4'-methanesulfonylbiphenyl-4-yl)-ethylamino]-pentanoyl}-tetrahydro-furo[3,2-b]pyrrol-3-one MEDIVIR AB (SE) 2011-03-29 US disclosed
US-20080234260-A1 Cysteine Protease inhibitors MEDIVIR AB (SE) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234260-A1 Cysteine Protease inhibitors CTSS, CTSZ, CTSK MAPT 4471/4885NPC1 482/4885RAB9A 1155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.